MannKind Co. (NASDAQ:MNKD - Free Report) - Research analysts at Leerink Partnrs cut their FY2026 EPS estimates for MannKind in a note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings per share of $0.22 for the year, down from their previous forecast of $0.23. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.
Several other analysts have also commented on MNKD. Leerink Partners assumed coverage on MannKind in a report on Monday, September 9th. They set an "outperform" rating and a $8.00 target price on the stock. Oppenheimer raised their price objective on shares of MannKind from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 28th. StockNews.com cut shares of MannKind from a "buy" rating to a "hold" rating in a research note on Saturday, December 7th. Finally, Royal Bank of Canada raised shares of MannKind from a "sector perform" rating to an "outperform" rating and increased their price target for the stock from $7.00 to $10.00 in a report on Thursday. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $8.86.
Get Our Latest Research Report on MNKD
NASDAQ MNKD opened at $6.30 on Friday. The firm has a market capitalization of $1.74 billion, a P/E ratio of 90.00 and a beta of 1.28. The stock has a 50-day simple moving average of $6.75 and a two-hundred day simple moving average of $6.01. MannKind has a fifty-two week low of $3.17 and a fifty-two week high of $7.63.
A number of large investors have recently modified their holdings of MNKD. Principal Financial Group Inc. lifted its stake in shares of MannKind by 401.8% in the third quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company's stock worth $1,060,000 after buying an additional 134,937 shares in the last quarter. Franklin Resources Inc. raised its holdings in MannKind by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 160,016 shares of the biopharmaceutical company's stock valued at $1,047,000 after acquiring an additional 4,603 shares during the last quarter. Geode Capital Management LLC lifted its stake in MannKind by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 6,338,928 shares of the biopharmaceutical company's stock worth $39,880,000 after purchasing an additional 24,031 shares in the last quarter. Barclays PLC boosted its holdings in shares of MannKind by 186.0% during the 3rd quarter. Barclays PLC now owns 519,865 shares of the biopharmaceutical company's stock worth $3,271,000 after purchasing an additional 338,121 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of MannKind in the third quarter valued at approximately $413,000. Hedge funds and other institutional investors own 49.55% of the company's stock.
In other MannKind news, insider Stuart A. Tross sold 55,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the completion of the transaction, the insider now owns 967,191 shares of the company's stock, valued at $7,099,181.94. This represents a 5.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven B. Binder sold 67,536 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $6.89, for a total value of $465,323.04. Following the completion of the transaction, the director now owns 1,075,026 shares in the company, valued at approximately $7,406,929.14. This trade represents a 5.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is owned by company insiders.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.